Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Curr Opin Rheumatol. 2019 May;31(3):300–306. doi: 10.1097/BOR.0000000000000589

Figure 1: Suggested approach to patients with rheumatoid arthritis undergoing major surgery.

Figure 1:

Suggestions based on recommendations for csDMARDs and biologics from 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons perioperative guidelines [29] and observational data on glucocorticoid risk [6,20,26-28].

* Surgeries with prosthetic material and abdominal surgeries are of particular concern

csDMARD = conventional synthetic disease modifying anti-rheumatic drug (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine); GC = glucocorticoids